Our Team
Gavin Liu
Gavin advises life sciences and healthcare companies and investors. His practice covers licensing and partnering transactions, asset purchases, divestments, and carve-out transactions, clinical trial, supply chain, and SaaS contracting, and financing/fundraising transactions. He also serves as fractional GC to multiple companies in the life sciences and healthcare space.
Gavin brings over a decade of experience, starting at the Latham & Watkins LLP Silicon Valley office as part of the Healthcare and Life Sciences corporate practice group working on both high stakes, cross-border partnering and day to day operational transactions. Subsequently he joined Astellas Pharma US LLC, where he led strategic transactions, alliance management and corporate venture capital financings. His combination of top tier law firm and in-house pharmaceutical industry experience allows him to bring his top tier technical skills to bear with a practical mindset in advising emerging and growth companies as they start and scale.
Select Strategic IP Transaction Matters:
Daiichi Sankyo in its global Phase 3 collaboration and license agreement with AstraZeneca for Enhertu™ (co-development and profit-sharing). $3B upfront payment.
Astellas in its global preclinical collaboration with Sutro Biopharma to discover, develop, and commercialize novel immunostimulatory ADCs. $1B+ potential deal value
Prothena in its global preclinical collaboration and option agreement to discover, develop, and commercialize novel antibodies for neurodegenerative diseases. $2B+ potential deal value
Astellas Gene Therapies in its exclusive license and option agreement with 4D Molecular Therapeutics to license its R100 vector for rare monogenic ophthalmic diseases. $900M+ potential deal value
Select Venture Investment Matters:
Astellas Venture Management in a strategic investment in Mogrify (in vivo cell reprogramming) as part of a $46M Series A
Astellas Venture Management in a strategic investment in Shinobi Therapeutics as part of a $51M Series A
Astellas Venture Management in a strategic investment in Neophore (DNA mismatch repair) as part of a $40M Series B
Education
UC Berkeley School of Law, J.D.
Duke University, B.S., Neuroscience
Bar Admissions
California
Managing Partner
Of Counsel
Tyler Hastings
Tyler advises startups and investors on venture capital financings and related corporate matters. Tyler was part of the Emerging Growth and Venture Capital group at DLA Piper in San Diego, working with companies across the globe, including local San Diego companies Epic Sciences, Qualcomm and Truvian, among others. Prior to DLA, Tyler was on the Corporate team at DaHui Lawyers in Beijing, working with companies including Boeing, General Electric, and Warburg Pincus. Tyler’s career has spanned across two continents and dozens of transactions, resulting in hundreds of millions of dollars in capital deployed, from pre‑seed SAFE financings to late‑stage growth equity and both buy‑ and sell‑side M+A.
Select Company‑Side Representations
Argonaut Manufacturing Services in its $45 million Series A financing
Epic Sciences in its $43 million Series F financing, and $24 million Series G financing
Pack Digital in its $3 million Series Seed financing
Select Investor‑Side Representations
An investor in the $87 million Series E financing of Tomorrow.io
Magnetar Capital in the $221 million Series B financing of CoreWeave
M12 (the venture arm of Microsoft) in the $16.5 million Series B financing of CodeOcean
Education
UCLA School of Law, JD
University of Vermont, BA
Bar Admissions
California